Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton

• Verfasst von: Knudsen, Peter Boldsen [VerfasserIn]
• Verfasst von: Hanna, Bola [VerfasserIn]
• Verfasst von: Ohl, S. [VerfasserIn]
• Verfasst von: Sellner, Leopold [VerfasserIn]
• Verfasst von: Zenz, Thorsten [VerfasserIn]
• Verfasst von: Döhner, H. [VerfasserIn]
• Verfasst von: Stilgenbauer, S. [VerfasserIn]
• Verfasst von: Larsen, T. O. [VerfasserIn]
• Verfasst von: Lichter, Peter [VerfasserIn]
• Verfasst von: Seiffert, Moritz [VerfasserIn]
• Titel: Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton
• Verf.angabe: P.B. Knudsen, B. Hanna, S. Ohl, L. Sellner, T. Zenz, H. Döhner, S. Stilgenbauer, T.O. Larsen, P. Lichter and M. Seiffert
• E-Jahr: 2014
• Jahr: 10 January 2014
• Umfang: 10 S.
• Fussnoten: Gesehen am 17.08.2020
• Titel Quelle: Enthalten in: Leukemia
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2014
• Band/Heft Quelle: 28(2014), 6, Seite 1289-1298
• ISSN Quelle: 1476-5551
• DOI: doi:10.1038/leu.2013.360
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1727161912

Abstract

Chronic lymphocytic leukemia (CLL) is an incurable malignancy of mature B cells. One of the major challenges in treatment of CLL is the achievement of a complete remission to prevent relapse of disease originating from cells within lymphoid tissues and subsequent chemoresistance. In search for novel drugs that target CLL cells in protective microenvironments, we performed a fungal extract screen using cocultures of primary CLL cells with bone marrow-derived stromal cells. A secondary metabolite produced by Penicillium aquamarinium was identified as Chaetoglobosin A (ChA), a member of the cytochalasan family that showed preferential induction of apoptosis in CLL cells, even under culture conditions that mimic lymphoid tissues. In vitro testing of 89 CLL cases revealed effective targeting of CLL cells by ChA, independent of bad prognosis characteristics, like 17p deletion or TP53 mutation. To provide insight into its mechanism of action, we showed that ChA targets filamentous actin in CLL cells and thereby induces cell-cycle arrest and inhibits membrane ruffling and cell migration. Our data further revealed that ChA prevents CLL cell activation and sensitizes them for treatment with PI3K and BTK inhibitors, suggesting this compound as a novel potential drug for CLL.